Тип публикации: статья из журнала

Год издания: 2021

Идентификатор DOI: 10.1134/S1990519X2103007X

Ключевые слова: cell cycle, G<inf>0</inf>, ki-67, melanoma, Quiescent cells, Vemurafenib

Аннотация: Vemurafenib revolutionized the treatment of melanomas which harbor mutations in BRAF oncogene whereas BRAF-negative tumors are resistant to its antitumor effects. Meanwhile tumor chemoresistance is associated with the presence of quiescent, resting-dormant (G₀-positive, Ki-67-negative) cancer cells in the heterogeneous cancer cell population. In order to test if BRAF-inhibitor can stimulate quiescence in melanoma cells, two melanoma cell lines (BRO and SK-MEL-2) were treated with the antitumor drug vemurafenib, and populations with G₁/G₀ cell cycle arrest were obtained. The latter were confirmed by negative staining with Ki-67 antibodies, and changes in the gene expression of cell cycle regulatory proteins, such as CDK4, CCND1 and CDKN1B.

Журнал: Cell and Tissue Biology

Выпуск журнала: Т. 15, № 3

Номера страниц: 227-235

ISSN журнала: 1990519X

Место издания: Санкт-Петербург

Издатель: Pleiades Publishing, Ltd. (Плеадес Паблишинг, Лтд)

• Nikolaeva E.D. (Voyno-Yasenetsky Krasnoyarsk State Medical University)
• Dubovtseva I.Y. (Voyno-Yasenetsky Krasnoyarsk State Medical University)
• Belonogov R.N. (Voyno-Yasenetsky Krasnoyarsk State Medical University)
• Narkevich A.N. (Voyno-Yasenetsky Krasnoyarsk State Medical University)
• Ruksha T.G. (Voyno-Yasenetsky Krasnoyarsk State Medical University)
• Moshev A.V. (Research Institute of Medical Problems of the North)
• Savchenko A.A. (Research Institute of Medical Problems of the North)

• Ядро РИНЦ (eLIBRARY.RU)